SMCC-DM1
Based on 12 publication(s) in Google Scholar
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.23%
- CAS No.: 1228105-51-8
- Formule: C51H66ClN5O16S
- Masse moléculaire:1072.61
-
Stockage:
-80°C, stored under nitrogen
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SMCC-DM1
More- Cancer Lett. 2023 Feb 1:554:216024. [Abstract]
- Mol Ther. 2022 Jul 6;30(7):2522-2536. [Abstract]
- Int J Biol Macromol. 2025 Aug 20;322(Pt 4):147025. [Abstract]
- Int J Mol Sci. 2022 Oct 15;23(20):12358. [Abstract]
- mBio. 2022 Feb 22;13(1):e0338421. [Abstract]
- J Pharm Sci. 2024 Aug;113(8):2443-2453. [Abstract]
- J Pharm Sci. 2024 May;113(5):1265-1274. [Abstract]
- AAPS J. 2025 May 9;27(4):91. [Abstract]
- Patent. US20260000782A1.
- Patent. US20250163175A1.
- Patent. US20250041438A1.
- Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):37-44. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
IF
-
WB
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform Drug-Linker Conjugates for ADC
More
Activité biologique
|
Maytansinoids |
SMCC-DM1 inhibits HCC1954 and MDA-MB-468 cells proliferation with IC50s of 17.2 and 49.9 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1228105-51-8
-
Appearance Solid
-
Masse moléculaire 1072.61
-
Formule C51H66ClN5O16S
-
Color White to off-white
-
SMILES
O=C(O[C@H]([C@@]1(C)[C@H]([C@@H]([C@@]2([H])OC(N[C@]3(O)C2)=O)C)O1)CC(N(C)C4=CC(C/C(C)=C/C=C/[C@H]3OC)=CC(OC)=C4Cl)=O)[C@@H](N(C(CCSC(C5=O)CC(N5CC6CCC(C(ON7C(CCC7=O)=O)=O)CC6)=O)=O)C)C
-
Synonyms
DM1-SMCC
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, stored under nitrogen
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
2023 Feb 1:554:216024. PMID: 36455759
SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]
SMCC-DM1 (10 mM). Dose-response analysis of the effect of cetuximab-DM1 (1-100000 nM; 120 h) on the proliferation of parental HCC1954 and HCC-TDM1R cells. IC50 values were represented in the graph and detailed in the table.
SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]
SMCC-DM1 (10 mM). In vivo effect of cetuximab-DM1 (i.p.; 15 mg/kg) on tumor growth in BALB/c nu/nu mice injected with HCC1954, HCC-TDM1R#19, or HCCTDM1R#20 cells.
SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]
SMCC-DM1 (10 mM). Colocalization (yellow) between cetuximab-DM1 (cet-DM1) (30 min-24 h; 10 nM) and LAMP1 occurred at the indicated incubation times in HCC1954 and HCC-TDM1R cells. Cetuximab-DM1 staining red, LAMP1: green, DAPI: blue.
SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Feb 1:554:216024. [Abstract]
SMCC-DM1 (10 mM). Western blot analyses showed the effect of cetuximab-DM1 (10 nM; 1-3 d) on the EGFR levels in HCC1954 and HCC-TDM1R cells.
-
Mol Ther
2022 Jul 6;30(7):2522-2536. PMID: 35440418
SMCC-DM1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2022 Jul 6;30(7):2522-2536. [Abstract]
ScFab Pigbak#2 and SMCC-DM1 were mixed in a molar ratio of 1:10 in PBS (pH 7.5) at 4 ℃ overnight. B16F10 cells were incubated with Pigbak#2-DM1 (0.05-50 nM) at various concentrations.
-
Int J Biol Macromol
Anovel anti-B7-H3 nanobody and its DM1 conjugate with marked anti-tumor activity against esophageal squamous cell carcinoma. [Abstract]2025 Aug 20;322(Pt 4):147025. PMID: 40846015 -
Int J Mol Sci
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. [Abstract]2022 Oct 15;23(20):12358. PMID: 36293219 -
mBio
A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. [Abstract]2022 Feb 22;13(1):e0338421. PMID: 35038908 -
J Pharm Sci
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads. [Abstract]2024 Aug;113(8):2443-2453. PMID: 38679234 -
J Pharm Sci
Agitation-Induced Aggregation of Lysine- and Interchain Cysteine-Linked Antibody-Drug Conjugates. [Abstract]2024 May;113(5):1265-1274. PMID: 38070776 -
AAPS J
Investigations of Influence of Antibody Binding Kinetics on Tumor Distribution and Anti-Tumor Efficacy. [Abstract]2025 May 9;27(4):91. PMID: 40341444 -
-
-
-
Monoclon Antib Immunodiagn Immunother
Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model. [Abstract]2020 Apr;39(2):37-44. PMID: 32182186
Solvant et solubilité
DMSO : 16.67 mg/mL (15.54 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (1.56 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (1.56 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9323 mL | 4.6615 mL | 9.3231 mL | 23.3076 mL |
| 5 mM | 0.1865 mL | 0.9323 mL | 1.8646 mL | 4.6615 mL | |
| 10 mM | 0.0932 mL | 0.4662 mL | 0.9323 mL | 2.3308 mL | |
| 15 mM | 0.0622 mL | 0.3108 mL | 0.6215 mL | 1.5538 mL |
SMCC-DM1 Related Classifications
HY-101070 Related Classifications
Powered by Bioz